Top Markets
Coin of the day
Gongwin Biopharm Holdings Co., Ltd. Gongwin Biopharm Holdings Co., Ltd.

Gongwin Biopharm Holdings Co., Ltd.

6617
Rank in Stocks #13748
Gongwin Biopharm Holdings Co., Ltd. is a clinical-stage biopharmaceutical... Gongwin Biopharm Holdings Co., Ltd. is a clinical-stage biopharmaceutical company specializing in the development of oncology therapeutics. The company's robust pipeline features several drug candidates, including PTS302, which has successfully concluded Phase III clinical trials for lung cancer. Additionally, PTS100 is currently progressing through Phase II clinical trials for liver cancer, while PTS-02 is being developed to address adenoid cystic carcinoma, and PTS500 targets malignant pleural effusion. Established in 2014, Gongwin Biopharm is headquartered in Taipei, Taiwan.
Share Price
$3.83
Market Cap
$464.45M
Change (1 day)
-1.63%
Change (1 year)
17.17%
Country
TW
Trade Gongwin Biopharm Holdings Co., Ltd. (6617)

Category

Operating Margin for Gongwin Biopharm Holdings Co., Ltd. (6617)
Operating Margin as of 2026 TTM: 0.00%
According to Gongwin Biopharm Holdings Co., Ltd. latest financial reports and stock price the company's current Operating Margin (TTM) is 0.00%. At the end of 2026 the company had an Operating Margin of 0.00%.
Operating Margin history for Gongwin Biopharm Holdings Co., Ltd. from 2026 to 2026
Operating Margin at the end of each year
Year Operating Margin Change
Not enough data for the provided dates.
Operating Margin for similar companies or competitors
Company Operating Margin Operating Margin Difference Country
1.62% -
US
0.00% -
US
1.03% -
US
0.00% -
US
-0.21% -
AU
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.